These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 22999151)

  • 1. An evaluation framework for funding drugs for rare diseases.
    Winquist E; Bell CM; Clarke JT; Evans G; Martin J; Sabharwal M; Gadhok A; Stevenson H; Coyle D
    Value Health; 2012; 15(6):982-6. PubMed ID: 22999151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First treatment for Hunter syndrome.
    FDA Consum; 2006; 40(6):5. PubMed ID: 17333554
    [No Abstract]   [Full Text] [Related]  

  • 3. Hunter syndrome: resolution of extensive typical skin lesions after 9 months of enzyme replacement therapy with idursulfase.
    Marín LL; Gutiérrez-Solana LG; Fernández AT
    Pediatr Dermatol; 2012; 29(3):369-70. PubMed ID: 21995841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Application of a policy framework for the public funding of drugs for rare diseases.
    Winquist E; Coyle D; Clarke JT; Evans GA; Seager C; Chan W; Martin J
    J Gen Intern Med; 2014 Aug; 29 Suppl 3(Suppl 3):S774-9. PubMed ID: 25029973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First experience of enzyme replacement therapy with idursulfase in Spanish patients with Hunter syndrome under 5 years of age: case observations from the Hunter Outcome Survey (HOS).
    Alcalde-Martín C; Muro-Tudelilla JM; Cancho-Candela R; Gutiérrez-Solana LG; Pintos-Morell G; Martí-Herrero M; Munguira-Aguado P; Galán-Gómez E
    Eur J Med Genet; 2010; 53(6):371-7. PubMed ID: 20709629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence and timing of infusion-related reactions in patients with mucopolysaccharidosis type II (Hunter syndrome) on idursulfase therapy in the real-world setting: a perspective from the Hunter Outcome Survey (HOS).
    Burton BK; Whiteman DA;
    Mol Genet Metab; 2011 Jun; 103(2):113-20. PubMed ID: 21439875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Idursulfase for the treatment of mucopolysaccharidosis II.
    Clarke LA
    Expert Opin Pharmacother; 2008 Feb; 9(2):311-7. PubMed ID: 18201153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Shift of focus in the financing of Hungarian drugs. Reimbursement for orphan drugs for treating rare diseases: financing of enzyme replacement therapy in Hungary].
    Szegedi M; Molnár MJ; Boncz I; Kosztolányi G
    Orv Hetil; 2014 Nov; 155(44):1735-41. PubMed ID: 25344850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The relationship between anti-idursulfase antibody status and safety and efficacy outcomes in attenuated mucopolysaccharidosis II patients aged 5 years and older treated with intravenous idursulfase.
    Barbier AJ; Bielefeld B; Whiteman DA; Natarajan M; Pano A; Amato DA
    Mol Genet Metab; 2013 Nov; 110(3):303-10. PubMed ID: 23988379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical dose ranging studies for enzyme replacement therapy with idursulfase in a knock-out mouse model of MPS II.
    Garcia AR; DaCosta JM; Pan J; Muenzer J; Lamsa JC
    Mol Genet Metab; 2007 Jun; 91(2):183-90. PubMed ID: 17459751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Agreement between results of meta-analyses from case reports and clinical studies, regarding efficacy and safety of idursulfase therapy in patients with mucopolysaccharidosis type II (MPS-II). A new tool for evidence-based medicine in rare diseases.
    Sampayo-Cordero M; Miguel-Huguet B; Pardo-Mateos A; Malfettone A; Pérez-García J; Llombart-Cussac A; Cortés J; Moltó-Abad M; Muñoz-Delgado C; Pérez-Quintana M; Pérez-López J
    Orphanet J Rare Dis; 2019 Oct; 14(1):230. PubMed ID: 31639024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Early response to idursulfase in a 31-year old male patient with Hunter syndrome].
    Pérez-Calvo J; Bergua Sanclemente I; López Moreno MJ; Torralba Cabeza MÁ; Amores Arriaga B
    Rev Clin Esp; 2011; 211(7):e42-5. PubMed ID: 21524741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome).
    Muenzer J; Gucsavas-Calikoglu M; McCandless SE; Schuetz TJ; Kimura A
    Mol Genet Metab; 2007 Mar; 90(3):329-37. PubMed ID: 17185020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Idursulfase enzyme replacement therapy in an adult patient with severe Hunter syndrome having a novel mutation of iduronate-2-sulfatase gene.
    Christianto A; Watanabe H; Nakajima T; Inazu T
    Clin Chim Acta; 2013 Aug; 423():66-8. PubMed ID: 23726270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful desensitization to idursulfase in a patient with type II mucopolysaccharidosis (Hunter syndrome).
    Serrano CD; Gomez JF
    J Investig Allergol Clin Immunol; 2011; 21(7):571-2. PubMed ID: 22312944
    [No Abstract]   [Full Text] [Related]  

  • 16. IgE-mediated anaphylaxis and allergic reactions to idursulfase in patients with Hunter syndrome.
    Kim J; Park MR; Kim DS; Lee JO; Maeng SH; Cho SY; Han Y; Ahn K; Jin DK
    Allergy; 2013 Jun; 68(6):796-802. PubMed ID: 23621439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical study of enzyme replacement therapy with idursulfase].
    Gutiérrez-Solana LG
    Rev Neurol; 2007 Feb; 44 Suppl 1():S7-S11. PubMed ID: 17345556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity of idursulfase and clinical outcomes in very young patients (16 months to 7.5 years) with mucopolysaccharidosis II (Hunter syndrome).
    Pano A; Barbier AJ; Bielefeld B; Whiteman DA; Amato DA
    Orphanet J Rare Dis; 2015 Apr; 10():50. PubMed ID: 25902842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Budget impact of rare diseases: proposal for a theoretical framework based on evidence from Bulgaria.
    Iskrov G; Jessop E; Miteva-Katrandzhieva T; Stefanov R
    Georgian Med News; 2015 May; (242):46-53. PubMed ID: 26042447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Idursulfase: a poor risk-benefit balance in type II mucopolysaccharidosis.
    Prescrire Int; 2008 Jun; 17(95):109. PubMed ID: 18630351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.